Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study

International Journal of Clinical Oncology

Volumn 16, Issue 5, 2011, Pages 506-511

  Nakayama, Goro ^a   Kodera, Yasuhiro ^a   Yokoyama, Hiroyuki ^b   Okuda, Naoto ^c   Watanabe, Takuya ^a   Tanaka, Chie ^a   Iwata, Naoki ^a   Ohashi, Norifumi ^a   Koike, Masahiko ^a   Fujiwara, Michitaka ^a   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Komaki Municipal Hospital   (Japan)

^c Chunichi Hospital   (Japan)

Author keywords

First line chemotherapy; Metastatic colorectal cancer; Neurotoxicity; Oxaliplatin; S 1

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; ANTINEOPLASTIC AGENT; OTERACIL; PLATINUM COMPLEX; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANOREXIA; ARTICLE; CANCER CONTROL; CANCER GROWTH; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; MAINTENANCE THERAPY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT PLANNING; VOMITING; CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; DRUG COMBINATION; METASTASIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; TEGAFUR;

EID: 84862855622     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0214-6     Document Type: Article

References (12)

1. De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947 (Pubitemid 30644117)
2. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30 (Pubitemid 41095110)
3. Goldstein D, Mitchell P, Michael M et al (2005) Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. Br J Cancer 92:832-837 (Pubitemid 40462626)
4. Tournigand C, Cervantes A, Figer A et al (2006) OPTIMOX1: a randomised study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 24:394-400 (Pubitemid 46630458)
5. Chibaudel B, Maindrault-Goebel F, Lledo G et al (2009) Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol 27:5727-5733
6. Douillard JY, Hoff PM, Skillings JR et al (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605-3616 (Pubitemid 34983220)
7. Carmichael J, Popiela T, Radstone D et al (2002) Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3617-3627 (Pubitemid 34983221)
8. Hoff PM, Ansari R, Batist G et al (2001) Comparison of oral capecitabine versus intravenous 5-fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer. Results of a randomized Phase III study. J Clin Oncol 19:2282-2292 (Pubitemid 32366981)
9. Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097-4106 (Pubitemid 33049527)
10. Shirasaki T (2009) Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jap J Clin Oncol 39:2-15
11. Shirao K, Ohtsu A, Takada H et al (2004) Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 100:2355-2366
12. Ohtsu A, Baba H, Sakata Y et al (2000) Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 83:141-145 (Pubitemid 30411708)